For the Inventor, By the Inventor

Enter assignee name

Lexington, MA, United States of America

Dicerna Pharmaceuticals, Inc.

Calculating rank

USPTO Granted Patents = 102

% Expired Patents = 8.8

CIPO Patents = 13

EPO Patents = 20

Trademarks = 5

Forward Citations = 402

Loading Chart...

Loading Chart...

37 inventors (with patents filed for the assignee):

Bob Dale Brown (79 out of 96 patents)

Henryk T Dudek (57 out of 65 patents)

Marc Abrams (14 out of 15 patents)

4. Cheng Lai (8 out of 8 patents)

5. Weimin Wang (7 out of 7 patents)

6. Utsav Saxena (7 out of 7 patents)

7. Natalie Wayne Pursell (6 out of 7 patents)

8. Martin Koser (5 out of 5 patents)

9. Naim Nazef (5 out of 5 patents)

10. Shanthi Ganesh (5 out of 6 patents)

11. Jihye Park (4 out of 5 patents)

12. Wen Han (4 out of 4 patents)

13. Anton Turanov (4 out of 4 patents)

14. Sujit Basu (3 out of 5 patents)

15. Qingyi Li (2 out of 9 patents)

Core Competencies:

Gene Expression

Hepatitis B

Double-Stranded RNA

Alpha-1 Antitrypsin

Glycolate Oxidase

Lactate Dehydrogenase

CRISPR Technology

Oligonucleotides

Immunotherapy

Nucleic Acid

Antithrombin 3

PCSK9

102 patents: Sort by Forward Citations

1. 12735710 - COMPOSITIONS AND METHODS FOR INHIBITING ANGPTL3 EXPRESSION (2026-09-15),

2. 12674169 - Compositions and methods for modulatingactivity (2026-07-07),

3. 12564601 - METHODS FOR TREATING HEPATITIS B INFECTION (2026-03-03),

4. 12435336 - Compositions and methods for inhibiting LPA expression (2025-10-07),

5. 12252691 - Compositions and methods for inhibiting LPA expression (2025-03-18),

6. 12234456 - Compositions and methods for modulating APOC3 expression (2025-02-25),

7. 12084662 - Compositions and methods for modulating PNPLA3 expression (2024-09-10),

8. 12077756 - Extended dicer substrate agents and methods for the specific inhibition of gene expression (2024-09-03),

9. 12037586 - 4'-phosphate analogs and oligonucleotides comprising the same (2024-07-16),

10. 12037358 - Compositions comprising reversibly modified oligonucleotides and uses thereof (2024-07-16),

11. 11952574 - Compositions and methods for inhibiting transmembrane serine protease 6 (TMPRSS6) expression (2024-04-09),

12. 11912996 - Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA (2024-02-27),

13. 11873493 - Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA (2024-01-16),

14. 11873488 - Double-stranded nucleic acid inhibitor molecules modified with Tm-increasing nucleotides (2024-01-16),

15. 11851658 - Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA (2023-12-26),

Company Overview

Dicerna Pharmaceuticals, Inc. is a biotechnology company based in Lexington, MA, specializing in gene expression inhibition. The company focuses on developing innovative therapies targeting diseases linked to gene expression, including hepatitis B and conditions related to alpha-1 antitrypsin deficiency. Dicerna leverages advanced technologies such as double-stranded RNA, CRISPR, and oligonucleotides to create potential treatments that address unmet medical needs, emphasizing precision medicine in its research and development efforts.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

102 Patents

#8 in Lexington, MA

#201 in Massachusetts

#3,726 in US

#7,656 in the World

Lexington, MA, United States of America

Dicerna Pharmaceuticals, Inc.

Forward Citations = 402

37 inventors:

Bob Dale Brown (79 out of 96 patents)

Henryk T Dudek (57 out of 65 patents)

Marc Abrams (14 out of 15 patents)

4. Cheng Lai (8 out of 8 patents)

5. Weimin Wang (7 out of 7 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Dicerna Pharmaceuticals, Inc.. Retrieved from https://idiyas.com/company/dicerna-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…